Expertise from a team you can trust
Our Recapitalization services redefine your business's financial landscape, providing a robust foundation for future growth. With a keen understanding of market dynamics, we tailor comprehensive recapitalization strategies to optimize your capital structure.
Whether you're seeking to enhance liquidity, reduce debt burdens, or fuel expansion initiatives, our industry-focused professionals guide you through a seamless process. Trust us to navigate the complexities of recapitalization, ensuring your business not only survives but thrives in today's dynamic economy.
Latest Recapitalization Transactions
OpenClinica Completes Growth Recapitalization with Thompson Street Capital Partners to Accelerate Enablement of Clinical Trials
RealTime Software Solutions Receives Strategic Investment from LLR Partners to Accelerate Growth and Product Innovation
UpStream Completes $45 Million Funding Round Led by Dragoneer to Revolutionize Care for Older Adults
WIRB-Copernicus Group (“WCG”) recapitalizes, led by Leonard Green & Partners, L.P.
Chonometriq Received an Investment from Full In Partners October 1, 2019
Biorasi Received a Majority Investment from Riordan, Lewis & Haden Equity Partners November 16, 2018
OmniSeq Received a Strategic Investment from HITACHI April 12, 2018
OmniSeq Received a Strategic Investment from LabCorp August 21, 2017
Chemical Computing Group Received a Majority Investment from Altaris June 8, 2017
Medsphere Raised $12,000,000 of Senior Debt
NaviNet Amount Raised Undisclosed, Senior Debt by a Placement Agent
ePharmaSolutions Received a Strategic Investment from Arsenal Capital Partners and WIRB-Copernicus Group September 24, 2014
Endpoint received a strategic investment from Chiltern March 31, 2010
Micronics raised $6M in Series B Preferred Shares October 16, 2008
Scandius Biomedical amount raised undisclosed preferred Equity Placement Agent
Gentiae Raised $16M in Series B Preferred Shares from Bay City Capital and CIBC January 3, 2007
Romark Laboratories Amount Raised Undisclosed
Bridge Laboratories Raised $35M in Series B Preferred Shares from Aisling Capital and Lehman Brothers June 14, 2006
Ixion Biotechnology Inc. Financial advisory
